UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000041163
Receipt number R000047006
Scientific Title Construction of prospective registry for idiopathic interstitial pneumonias and building of their epidemiological data based on Web-based interactive multidisciplinary discussion - development of diagnostic artificial intelligence and novel biomarkers -
Date of disclosure of the study information 2020/07/20
Last modified on 2023/01/21 15:44:04

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Construction of prospective registry for idiopathic interstitial pneumonias and building of their epidemiological data based on Web-based interactive multidisciplinary discussion - development of diagnostic artificial intelligence and novel biomarkers -

Acronym

IBiS study

Scientific Title

Construction of prospective registry for idiopathic interstitial pneumonias and building of their epidemiological data based on Web-based interactive multidisciplinary discussion - development of diagnostic artificial intelligence and novel biomarkers -

Scientific Title:Acronym

IBiS study

Region

Japan


Condition

Condition

Idiopathic interstitial pneumonias

Classification by specialty

Pneumology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The aim of this study is to establish a prospective registry of idiopathic interstitial pneumonias (IIPs) and to reveal the epidemiology of IIPs based on multidisciplinary discussion (MDD) diagnosis.

Basic objectives2

Others

Basic objectives -Others

To develop biomarkers useful for diagnosing and classifying IIPs and for predicting disease progression and prognosis of patients with IIPs, and to develop an artificial intelligence (AI)-based diagnostic system for IIPs.

Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Relative prevalence of IIPs based on MDD diagnosis

Key secondary outcomes

- Disease progression rate by IIPs classification
- Cumulative survival rate by IIPs classification
- Diagnostic accuracy and prognostic stratification of AI diagnostic system
- Diagnostic accuracy and prognostic stratification of novel biomarkers
- Cumulative incidence of acute exacerbation by IIPs classification
- Cumulative incidence of connective tissue disease/vasculitis by IIPs classification
- Cumulative incidence of lung cancer by IIPs classification
- Changes in respiratory function by IIPs classification
- Proposal-based exploratory research using this cohort data
- Search for new biomarkers using stocked serum samples
- Survey of end-of-life care/palliative care


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients newly diagnosed with IIPs at each hospital in Japan

Key exclusion criteria

Cases that meet any of the following criteria are excluded from this study.
- Patients who have difficulty cooperating with various tests required in this study, such as respiratory function tests
- Patients who have undergone lobectomy or more extensive pneumonectomy by the time of registration
- Patients who have not been interviewed or tested enough to diagnose IIPs by the time the central MDD diagnosis team makes a diagnosis

Target sample size

1000


Research contact person

Name of lead principal investigator

1st name Takafumi
Middle name
Last name Suda

Organization

Hamamatsu University School of Medicine

Division name

Second Division, Department of Internal Medicine

Zip code

4313192

Address

1-20-1 Handayama Higashi-ku, Hamamatsu, 431-3192 Japan

TEL

+81-53-435-2263

Email

suda@hama-med.ac.jp


Public contact

Name of contact person

1st name Hironao
Middle name
Last name Hozumi

Organization

Hamamatsu University School of Medicine

Division name

Second Division, Department of Internal Medicine

Zip code

4313192

Address

1-20-1 Handayama Higashi-ku, Hamamatsu, 431-3192 Japan

TEL

+81-53-435-2263

Homepage URL

https://portal.mdd.systems/

Email

hozumi@hama-med.ac.jp


Sponsor or person

Institute

Hamamatsu University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Japan Agency for Medical Research and Development

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Hamamatsu University School of Medicine

Address

1-20-1 Handayama Higashi-ku, Hamamatsu, 431-3192 Japan

Tel

+81-53-435-2680

Email

rinri@hama-med.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 07 Month 20 Day


Related information

URL releasing protocol

https://portal.mdd.systems/

Publication of results

Unpublished


Result

URL related to results and publications

https://portal.mdd.systems/

Number of participants that the trial has enrolled

1160

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2020 Year 06 Month 18 Day

Date of IRB

2020 Year 07 Month 06 Day

Anticipated trial start date

2020 Year 09 Month 01 Day

Last follow-up date

2027 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

- Prospective collection of clinical findings (patient background/characteristics, blood tests, physiological tests, autoantibodies, connective tissue disease/vasculitis-related symptoms and physical findings), chest HRCT images, and lung pathological specimens
- MDD diagnosis by pulmonologist, thoracic radiologist, and lung pathologist at enrollment and at end of follow-up
- Clinical outcomes (survival/death, cause of death, acute exacerbation, change of diagnosis, lung cancer, connective tissue disease/vasculitis)


Management information

Registered date

2020 Year 07 Month 20 Day

Last modified on

2023 Year 01 Month 21 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047006


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name